CHRS trades 377.8% below Wall Street's consensus target of $6.02.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CHRS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 17 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Coherus Oncology, Inc. (CHRS) has a Wall Street consensus price target of $6.02, based on estimates from 17 covering analysts. With the stock currently trading at $1.26, this represents a potential upside of +377.8%. The company has a market capitalization of $154M.
Analyst price targets range from a low of $1.05 to a high of $11.00, representing a 165% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CHRS trades at a trailing P/E of -0.9x. Analysts expect EPS to grow -4.7% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRGOPerrigo Company plc | $1.9B | $13.84 | $36.20 | +161.6% | Hold | 6.2x | 36 |
 AMRXAmneal Pharmaceuticals, Inc. | $6.2B | $19.33 | $22.25 | +15.1% | Buy | 19.1x | 17 |
 HCMHUTCHMED (China) Limited | $2.5B | $14.37 | $22.78 | +58.5% | Buy | 45.7x | 10 |
 TGTXTG Therapeutics, Inc. | $8.6B | $56.00 | $80.50 | +43.8% | Buy | 55.8x | 13 |
 MGNXMacroGenics, Inc. | $242M | $3.80 | $6.00 | +57.9% | Buy | — | 22 |
 VTRSViatris Inc. | $19.9B | $17.12 | $20.50 | +19.7% | Hold | 6.8x | 13 |
 PFGCPerformance Food Group Co | $14.3B | $90.79 | $127.33 | +40.2% | Buy | 19.7x | 26 |
 SGMTSagimet Biosciences Inc. | $340M | $10.42 | $18.00 | +72.7% | Buy | — | 8 |
 AGENAgenus Inc. | $350M | $8.40 | $25.00 | +197.6% | Buy | 10.8x | 11 |
 IMVTImmunovant, Inc. | $7.1B | $34.54 | $40.00 | +15.8% | Buy | — | 23 |
Quick answers to the most common questions about buying CHRS stock.
The consensus Wall Street price target for CHRS is $6.02, representing 377.8% upside from the current price of $1.26. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CHRS has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $6.02 implies 377.8% upside from current levels.
CHRS's current price is $1.26 with a consensus target of $6.02 (377.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $11 for CHRS, while the most conservative target is $1.05. The consensus of $6.02 represents the median expectation. These targets typically reflect 12-month expectations.
CHRS is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CHRS stock forecast based on 17 Wall Street analysts shows a consensus price target of $6.02, with estimates ranging from $1.05 (bear case) to $11 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CHRS, with a "Buy" consensus rating and $6.02 price target (377.8% upside). 14 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CHRS analyst price targets range from $1.05 to $11, a 165% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.02 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.